Table 1

Disproportionality analysis using different measures to identify potential association between different OACs and the risk of OA and joint replacement

Outcome of interestDrug of exposure groupComparator groupROR (95% CI)Exp (IC) (95% CI)
No of casesNo of non-casesNo of casesNo of non-cases
Warfarin vs all other drugs
 OA19299 74610 8328 011 2671.42 (1.23 to 1.64)1.64 (1.33 to 2.01)
 OA-related adverse event25499 68412 8678 009 2321.59 (1.40 to 1.80)1.91 (1.60 to 2.29)
 Knee or hip replacements18199 75789998 013 1001.62 (1.39 to 1.87)1.96 (1.58 to 2.42)
 Osteoarthropathies25899 68013 1498 008 9501.58 (1.39 to 1.78)1.89 (1.59 to 2.26)
Warfarin vs NOACs
 OA19299 746170207 3432.35 (1.91 to 2.89)2.01 (1.56 to 2.58)
 OA-related adverse event25499 684197207 3162.68 (2.23 to 3.23)2.19 (1.75 to 2.73)
 Knee or hip replacements18199 757216207 2971.74 (1.43 to 2.12)1.61 (1.25 to 2.08)
 Osteoarthropathies25899 680198207 3152.71 (2.25 to 3.26)2.21 (1.77 to 2.75)
NOACs vs all other drugs
 OA170207 34310 8547 903 6700.60 (0.51 to 0.69)0.48 (0.39 to 0.60)
 OA-related adverse event197207 31612 9247 901 6000.58 (0.50 to 0.67)0.46 (0.38 to 0.57)
 Knee or hip replacements216207 29789647 905 5600.92 (0.80 to 1.05)0.88 (0.73 to 1.07)
 Osteoarthropathies198207 31513 2097 901 3150.57 (0.50 to 0.66)0.45 (0.37 to 0.55)
  • IC, information component; NOACs, novel OACs; OA, osteoarthritis; OACs, oral anticoagulants; ROR, reporting OR.